SK288119B6 - Von Willebrand Factor (vWF) cleaving protease polypeptide, nucleic acid encoding the polypeptide and use of polypeptide - Google Patents
Von Willebrand Factor (vWF) cleaving protease polypeptide, nucleic acid encoding the polypeptide and use of polypeptide Download PDFInfo
- Publication number
- SK288119B6 SK288119B6 SK802-2003A SK8022003A SK288119B6 SK 288119 B6 SK288119 B6 SK 288119B6 SK 8022003 A SK8022003 A SK 8022003A SK 288119 B6 SK288119 B6 SK 288119B6
- Authority
- SK
- Slovakia
- Prior art keywords
- vwf
- polypeptide
- seq
- protease
- activity
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 194
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 169
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 167
- 108091005804 Peptidases Proteins 0.000 title claims abstract description 50
- 239000004365 Protease Substances 0.000 title claims abstract description 50
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 34
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 20
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 20
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 title claims abstract 6
- 108010047303 von Willebrand Factor Proteins 0.000 title abstract description 131
- 102100036537 von Willebrand factor Human genes 0.000 title abstract description 131
- 229960001134 von willebrand factor Drugs 0.000 title abstract description 130
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 43
- 239000000203 mixture Substances 0.000 claims abstract description 20
- 238000004519 manufacturing process Methods 0.000 claims abstract description 11
- 208000001435 Thromboembolism Diseases 0.000 claims abstract description 7
- 208000007536 Thrombosis Diseases 0.000 claims abstract description 4
- 238000011321 prophylaxis Methods 0.000 claims abstract description 4
- 230000000694 effects Effects 0.000 claims description 40
- 238000003776 cleavage reaction Methods 0.000 claims description 35
- 230000007017 scission Effects 0.000 claims description 33
- 239000012634 fragment Substances 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 27
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 19
- 239000013598 vector Substances 0.000 claims description 19
- 239000013604 expression vector Substances 0.000 claims description 16
- 102000003780 Clusterin Human genes 0.000 claims description 15
- 108090000197 Clusterin Proteins 0.000 claims description 15
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 14
- 241001465754 Metazoa Species 0.000 claims description 10
- 229940122055 Serine protease inhibitor Drugs 0.000 claims description 7
- 101710102218 Serine protease inhibitor Proteins 0.000 claims description 7
- MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 claims description 7
- 229960005051 fluostigmine Drugs 0.000 claims description 7
- 229910021645 metal ion Inorganic materials 0.000 claims description 7
- 239000003001 serine protease inhibitor Substances 0.000 claims description 7
- 230000002797 proteolythic effect Effects 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 108010032088 Calpain Proteins 0.000 claims description 4
- 102000007590 Calpain Human genes 0.000 claims description 4
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 4
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 4
- -1 peptidyl diazomethylketone Chemical compound 0.000 claims description 4
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 claims description 3
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 claims description 3
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 claims description 3
- 208000031814 IgA Vasculitis Diseases 0.000 claims description 3
- 208000009567 Neonatal Alloimmune Thrombocytopenia Diseases 0.000 claims description 3
- 206010037549 Purpura Diseases 0.000 claims description 3
- 241001672981 Purpura Species 0.000 claims description 3
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 claims description 3
- 208000030372 neonatal thrombocytopenia Diseases 0.000 claims description 3
- 230000001732 thrombotic effect Effects 0.000 claims description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- 108091005670 ADAMTS13 Proteins 0.000 abstract description 89
- 102100032290 A disintegrin and metalloproteinase with thrombospondin motifs 13 Human genes 0.000 abstract description 88
- 238000002360 preparation method Methods 0.000 abstract description 8
- 238000002560 therapeutic procedure Methods 0.000 abstract description 5
- 210000004027 cell Anatomy 0.000 description 62
- 108090000623 proteins and genes Proteins 0.000 description 49
- 102000004169 proteins and genes Human genes 0.000 description 44
- 235000018102 proteins Nutrition 0.000 description 42
- 102000035195 Peptidases Human genes 0.000 description 41
- 210000002381 plasma Anatomy 0.000 description 35
- 239000000872 buffer Substances 0.000 description 28
- 239000000499 gel Substances 0.000 description 25
- 235000001014 amino acid Nutrition 0.000 description 23
- 229920002684 Sepharose Polymers 0.000 description 22
- 150000001413 amino acids Chemical class 0.000 description 22
- 230000002829 reductive effect Effects 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 108700024394 Exon Proteins 0.000 description 13
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 239000002299 complementary DNA Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 238000000746 purification Methods 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 238000001042 affinity chromatography Methods 0.000 description 9
- 238000002523 gelfiltration Methods 0.000 description 9
- 239000008363 phosphate buffer Substances 0.000 description 9
- ILXAOQAXSHVHTM-UHFFFAOYSA-M sodium;2-amino-2-(hydroxymethyl)propane-1,3-diol;chloride Chemical compound [Na+].[Cl-].OCC(N)(CO)CO ILXAOQAXSHVHTM-UHFFFAOYSA-M 0.000 description 9
- 102000029750 ADAMTS Human genes 0.000 description 7
- 108091022879 ADAMTS Proteins 0.000 description 7
- 240000004322 Lens culinaris Species 0.000 description 7
- 235000014647 Lens culinaris subsp culinaris Nutrition 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 230000036961 partial effect Effects 0.000 description 7
- 108091033319 polynucleotide Proteins 0.000 description 7
- 102000040430 polynucleotide Human genes 0.000 description 7
- 239000002157 polynucleotide Substances 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 210000004962 mammalian cell Anatomy 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000013592 cell lysate Substances 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 210000000349 chromosome Anatomy 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 108010088842 Fibrinolysin Proteins 0.000 description 4
- 102000004961 Furin Human genes 0.000 description 4
- 108090001126 Furin Proteins 0.000 description 4
- 102000005741 Metalloproteases Human genes 0.000 description 4
- 108010006035 Metalloproteases Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000004255 ion exchange chromatography Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229940012957 plasmin Drugs 0.000 description 4
- 230000017854 proteolysis Effects 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 101800001224 Disintegrin Proteins 0.000 description 3
- 108010054218 Factor VIII Proteins 0.000 description 3
- 102000001690 Factor VIII Human genes 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 241000714474 Rous sarcoma virus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102000002938 Thrombospondin Human genes 0.000 description 3
- 108060008245 Thrombospondin Proteins 0.000 description 3
- 101710120037 Toxin CcdB Proteins 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000005571 anion exchange chromatography Methods 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000011210 chromatographic step Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 229960000301 factor viii Drugs 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000000816 peptidomimetic Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 238000007670 refining Methods 0.000 description 3
- VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102000043853 ADAMTS13 Human genes 0.000 description 2
- 241000701822 Bovine papillomavirus Species 0.000 description 2
- 229940121926 Calpain inhibitor Drugs 0.000 description 2
- 102100035037 Calpastatin Human genes 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 101000798281 Homo sapiens A disintegrin and metalloproteinase with thrombospondin motifs 13 Proteins 0.000 description 2
- VHJLVAABSRFDPM-IMJSIDKUSA-N L-1,4-dithiothreitol Chemical compound SC[C@H](O)[C@@H](O)CS VHJLVAABSRFDPM-IMJSIDKUSA-N 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 239000012506 Sephacryl® Substances 0.000 description 2
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 208000027276 Von Willebrand disease Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000002788 anti-peptide Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 108010079785 calpain inhibitors Proteins 0.000 description 2
- 108010044208 calpastatin Proteins 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 201000011461 pre-eclampsia Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000003079 salivary gland Anatomy 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- CNNSWSHYGANWBM-UHFFFAOYSA-N 6-chloro-2,3-dimethylquinoxaline Chemical compound C1=C(Cl)C=C2N=C(C)C(C)=NC2=C1 CNNSWSHYGANWBM-UHFFFAOYSA-N 0.000 description 1
- 102000051389 ADAMTS5 Human genes 0.000 description 1
- 108091005663 ADAMTS5 Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000015957 Acquired Von Willebrand disease Diseases 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100030010 Calpain-7 Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 101800000620 Disintegrin-like Proteins 0.000 description 1
- 230000010777 Disulfide Reduction Effects 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000793684 Homo sapiens Calpain-7 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000598171 Human adenovirus sp. Species 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- BJFJQOMZCSHBMY-YUMQZZPRSA-N Met-Val Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(O)=O BJFJQOMZCSHBMY-YUMQZZPRSA-N 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- AFWBWPCXSWUCLB-WDSKDSINSA-N Pro-Ser Chemical compound OC[C@@H](C([O-])=O)NC(=O)[C@@H]1CCC[NH2+]1 AFWBWPCXSWUCLB-WDSKDSINSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- UJTZHGHXJKIAOS-WHFBIAKZSA-N Ser-Gln Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O UJTZHGHXJKIAOS-WHFBIAKZSA-N 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000009694 Type 2 von Willebrand Disease Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000002869 basic local alignment search tool Methods 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000011545 carbonate/bicarbonate buffer Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000019256 formaldehyde Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000004023 fresh frozen plasma Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HOVAGTYPODGVJG-VEIUFWFVSA-N methyl alpha-D-mannoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O HOVAGTYPODGVJG-VEIUFWFVSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000002071 myeloproliferative effect Effects 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000007030 peptide scission Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108010031719 prolyl-serine Proteins 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 201000006681 severe congenital neutropenia Diseases 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- AYEKOFBPNLCAJY-UHFFFAOYSA-O thiamine pyrophosphate Chemical compound CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N AYEKOFBPNLCAJY-UHFFFAOYSA-O 0.000 description 1
- 125000000858 thiocyanato group Chemical group *SC#N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 101150060219 tsp-1 gene Proteins 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 208000017129 von Willebrand disease 2 Diseases 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 210000004269 weibel-palade body Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
- C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
- C12N9/6416—Metalloendopeptidases (3.4.24)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Chemical Or Physical Treatment Of Fibers (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72125400A | 2000-11-22 | 2000-11-22 | |
| US09/833,328 US6926894B2 (en) | 2000-11-22 | 2001-04-12 | Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV |
| PCT/EP2001/013391 WO2002042441A2 (en) | 2000-11-22 | 2001-11-20 | VON WILLEBRAND FACTOR (vWF) CLEAVING PROTEASE POLYPEPTIDE, NUCLEIC ACID ENCODING THE POLYPEPTIDE AND USE OF POLYPEPTIDE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK8022003A3 SK8022003A3 (en) | 2004-04-06 |
| SK288119B6 true SK288119B6 (sk) | 2013-09-03 |
Family
ID=27110398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK802-2003A SK288119B6 (sk) | 2000-11-22 | 2001-11-20 | Von Willebrand Factor (vWF) cleaving protease polypeptide, nucleic acid encoding the polypeptide and use of polypeptide |
Country Status (15)
| Country | Link |
|---|---|
| US (7) | US6926894B2 (cs) |
| EP (1) | EP1346034B1 (cs) |
| AT (1) | ATE423194T1 (cs) |
| AU (1) | AU2002218306A1 (cs) |
| CZ (1) | CZ305602B6 (cs) |
| DE (1) | DE60137710D1 (cs) |
| DK (1) | DK1346034T3 (cs) |
| ES (1) | ES2322126T3 (cs) |
| HU (1) | HU227996B1 (cs) |
| NZ (1) | NZ526616A (cs) |
| PT (1) | PT1346034E (cs) |
| RU (1) | RU2003118441A (cs) |
| SI (1) | SI1346034T1 (cs) |
| SK (1) | SK288119B6 (cs) |
| WO (1) | WO2002042441A2 (cs) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6926894B2 (en) | 2000-11-22 | 2005-08-09 | Baxter Aktiengesellschaft | Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV |
| JP2003284570A (ja) * | 2001-04-25 | 2003-10-07 | Chemo Sero Therapeut Res Inst | フォンビルブラント因子（ｖＷＦ）切断酵素 |
| US7037658B2 (en) | 2001-08-16 | 2006-05-02 | Regents Of University Of Michigan | Methods and compositions for detecting variant ADAMTS13 genes |
| DE20213920U1 (de) | 2002-07-03 | 2003-01-16 | Böhm, Martina, 60439 Frankfurt | Diagnostikum zum Nachweis der den von Willebrand-Faktorspaltenden Aktivität von ADAMTS13 |
| AU2012203101B2 (en) * | 2002-09-25 | 2014-10-02 | Km Biologics Co., Ltd. | Antibody against enzyme specifically cleaving von villebrand factor and assay system using the same |
| CN1701117B (zh) * | 2002-09-25 | 2011-04-20 | 财团法人化学及血清疗法研究所 | 针对von willebrand 因子切割酶的抗体及利用所述抗体的分析系统 |
| US20040185042A1 (en) * | 2003-03-20 | 2004-09-23 | Friedrich Scheiflinger | Immunoadsorption of anti-von Willebrand Factor cleaving protease antibodies |
| US7763430B2 (en) | 2003-04-22 | 2010-07-27 | Baxter International Inc. | Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies |
| CA2550939A1 (en) | 2003-12-22 | 2005-07-07 | Mitsubishi Kagaku Iatron, Inc. | Method of detecting thrombosis by measuring von willebrand factor-cleaving protease |
| EP1568782A1 (de) * | 2004-02-25 | 2005-08-31 | Clemens Bockmeyer | Diagnose und Therapie von ADAMTS-13 assoziierten Erkrankungen |
| ES2348397T3 (es) * | 2004-07-19 | 2010-12-03 | American Diagnostica Inc. | Metodos para medir la actividad de adamts13 en la superficie de las plaquetas. |
| US7270976B2 (en) * | 2004-07-19 | 2007-09-18 | American Diagnostica, Inc. | Methods for measuring ADAMTS13 activity and protein on platelets and in plasma |
| US20080138837A1 (en) * | 2004-07-19 | 2008-06-12 | Robert Greenfield | Methods and kits for detecting and measuring ADAMTS13/FXI complexes |
| CA2606351C (en) * | 2005-06-17 | 2016-12-13 | Baxter International Inc. | Adamts13-comprising compositions having thrombolytic activity |
| US7893616B2 (en) * | 2006-02-27 | 2011-02-22 | Ohio State University | Process to determine enzyme activity |
| FR2918375B1 (fr) * | 2007-07-05 | 2009-10-16 | Lab Francais Du Fractionnement | Utilisation d'un support de chromatographie pour reduire la quantite d'adamts13 dans une solution derivee du plasma |
| AU2008345231B2 (en) | 2007-12-27 | 2014-09-11 | Takeda Pharmaceutical Company Limited | Cell culture processes |
| US8945895B2 (en) | 2009-07-31 | 2015-02-03 | Baxter International Inc. | Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof |
| KR101808496B1 (ko) | 2009-07-31 | 2017-12-12 | 백스터 인터내셔널 인코포레이티드 | Adamts 단백질 발현을 위한 세포 배양 배지 |
| EP3834841B1 (en) | 2009-09-21 | 2023-05-17 | Takeda Pharmaceutical Company Limited | Stabilized liquid and lyophilized adamts13 formulations |
| SG186936A1 (en) * | 2010-07-08 | 2013-02-28 | Baxter Int | METHOD OF PRODUCING RECOMBINANT HIGH MOLECULAR WEIGHT vWF IN CELL CULTURE |
| US9488625B2 (en) | 2010-12-15 | 2016-11-08 | Baxalta GmbH | Purification of factor VIII using a conductivity gradient |
| ES2554231T3 (es) | 2011-05-19 | 2015-12-17 | Baxalta Incorporated | Detección de complejos de ADAMTS13-anticuerpo en circulación |
| KR102006151B1 (ko) | 2012-11-27 | 2019-10-10 | 삼성디스플레이 주식회사 | 터치를 인식하고 전기 촉각 자극을 제공하는 표시 장치 및 그 구동 방법 |
| AU2013203062C1 (en) | 2013-03-15 | 2018-06-28 | Takeda Pharmaceutical Company Limited | Subcutaneous administration of adamts13 |
| US10639307B2 (en) * | 2015-05-15 | 2020-05-05 | Children's Medical Center Corporation | Methods relating to the diagnosis and treatment of preeclampsia comprising administration of ADAMTS13 polypeptides |
| SG11201900853SA (en) | 2016-08-04 | 2019-02-27 | Baxalta Inc | Use of adamts13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome |
| FR3069156B1 (fr) * | 2017-07-21 | 2019-08-09 | Universite de Bordeaux | Clusterine pour son utilisation dans le traitement des micro-angiopathies thrombotiques |
| EP4037704A4 (en) | 2019-10-04 | 2023-04-26 | The Children's Medical Center Corporation | Adamts13 treatment to enhance graft survival |
| KR20230005192A (ko) | 2020-04-02 | 2023-01-09 | 다케다 야쿠힌 고교 가부시키가이샤 | Adamts13 변이체, 조성물 및 그의 용도 |
| WO2021234458A1 (en) | 2020-05-22 | 2021-11-25 | Takeda Pharmaceutical Company Limited | Adamts13 compositions and methods for treating and diagnosing complications of coronavirus disease |
| KR20240137043A (ko) * | 2022-01-26 | 2024-09-19 | 아이덱스 래보러토리즈, 인코포레이티드 | 진행성 만성 신장 질환과 안정한 만성 신장 질환을 구별하기 위한 방법 및 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6068838A (en) * | 1996-04-29 | 2000-05-30 | Baxter Aktiengesellschaft | Purified multimerase |
| AT406867B (de) * | 1997-02-27 | 2000-10-25 | Immuno Ag | Verfahren zur gewinnung von hochreinem vwf oder faktor viii/vwf-komplex |
| US20010049106A1 (en) | 2000-04-27 | 2001-12-06 | Leonard Buckbinder | ADAMTS polypeptides, nucleic acids encoding them, and uses thereof |
| US6926894B2 (en) | 2000-11-22 | 2005-08-09 | Baxter Aktiengesellschaft | Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV |
| US7070532B2 (en) * | 2003-08-26 | 2006-07-04 | General Motors Corporation | Planetary transmission having a rotating-type torque-transmitting mechanism with a stationary piston |
-
2001
- 2001-04-12 US US09/833,328 patent/US6926894B2/en not_active Expired - Lifetime
- 2001-11-20 WO PCT/EP2001/013391 patent/WO2002042441A2/en not_active Application Discontinuation
- 2001-11-20 CZ CZ2003-1718A patent/CZ305602B6/cs not_active IP Right Cessation
- 2001-11-20 DK DK01997546T patent/DK1346034T3/da active
- 2001-11-20 NZ NZ526616A patent/NZ526616A/en not_active IP Right Cessation
- 2001-11-20 EP EP01997546A patent/EP1346034B1/en not_active Expired - Lifetime
- 2001-11-20 AT AT01997546T patent/ATE423194T1/de active
- 2001-11-20 ES ES01997546T patent/ES2322126T3/es not_active Expired - Lifetime
- 2001-11-20 PT PT01997546T patent/PT1346034E/pt unknown
- 2001-11-20 SK SK802-2003A patent/SK288119B6/sk not_active IP Right Cessation
- 2001-11-20 RU RU2003118441/13A patent/RU2003118441A/ru not_active Application Discontinuation
- 2001-11-20 HU HU0400588A patent/HU227996B1/hu unknown
- 2001-11-20 DE DE60137710T patent/DE60137710D1/de not_active Expired - Lifetime
- 2001-11-20 AU AU2002218306A patent/AU2002218306A1/en not_active Abandoned
- 2001-11-20 SI SI200130908T patent/SI1346034T1/sl unknown
-
2005
- 2005-06-23 US US11/166,288 patent/US7501117B2/en not_active Expired - Lifetime
-
2008
- 2008-02-15 US US12/032,553 patent/US8703426B2/en not_active Expired - Lifetime
- 2008-07-11 US US12/171,934 patent/US8703429B2/en not_active Expired - Lifetime
-
2009
- 2009-02-12 US US12/370,129 patent/US7910094B2/en not_active Expired - Fee Related
-
2014
- 2014-04-07 US US14/247,116 patent/US9309506B2/en not_active Expired - Lifetime
-
2016
- 2016-04-08 US US15/094,734 patent/US20170065686A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US7910094B2 (en) | 2011-03-22 |
| US8703426B2 (en) | 2014-04-22 |
| NZ526616A (en) | 2005-04-29 |
| US9309506B2 (en) | 2016-04-12 |
| US20170065686A1 (en) | 2017-03-09 |
| US20140335071A1 (en) | 2014-11-13 |
| US20090017467A1 (en) | 2009-01-15 |
| US20050266528A1 (en) | 2005-12-01 |
| DK1346034T3 (da) | 2009-05-11 |
| CZ305602B6 (cs) | 2016-01-06 |
| SI1346034T1 (sl) | 2009-08-31 |
| HUP0400588A2 (hu) | 2004-06-28 |
| DE60137710D1 (de) | 2009-04-02 |
| HU227996B1 (hu) | 2012-08-28 |
| AU2002218306A1 (en) | 2002-06-03 |
| US7501117B2 (en) | 2009-03-10 |
| US6926894B2 (en) | 2005-08-09 |
| EP1346034B1 (en) | 2009-02-18 |
| CZ20031718A3 (cs) | 2004-07-14 |
| HUP0400588A3 (en) | 2006-01-30 |
| US20080176312A1 (en) | 2008-07-24 |
| ATE423194T1 (de) | 2009-03-15 |
| WO2002042441A3 (en) | 2002-08-08 |
| ES2322126T3 (es) | 2009-06-17 |
| WO2002042441A2 (en) | 2002-05-30 |
| EP1346034A2 (en) | 2003-09-24 |
| US20020136713A1 (en) | 2002-09-26 |
| RU2003118441A (ru) | 2004-12-10 |
| PT1346034E (pt) | 2009-05-05 |
| US20090203110A1 (en) | 2009-08-13 |
| US8703429B2 (en) | 2014-04-22 |
| SK8022003A3 (en) | 2004-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1346034B1 (en) | VON WILLEBRAND FACTOR (vWF) CLEAVING PROTEASE POLYPEPTIDE, NUCLEIC ACID ENCODING THE POLYPEPTIDE AND USE OF POLYPEPTIDE | |
| US5202253A (en) | Monoclonal antibody specific for protein C and antibody purification method | |
| US5043429A (en) | Protein fragments containing Factor VIII binding domain of von Willebrand Factor | |
| JPH10500294A (ja) | 組換え型ｈｋ２ポリペプチド | |
| CA2222419A1 (en) | A novel form of dipeptidylpeptidase iv (cd26) found in human serum, antibodies thereto, and uses therefor | |
| EP0407544B1 (en) | Monoclonal antibody against protein c | |
| BORGEL et al. | Implication of protein S thrombin-sensitive region with membrane binding via conformational changes in the γ-carboxyglutamic acid-rich domain | |
| JP2008532536A (ja) | 新規の非タンパク分解起源の可溶性ｅｐｃｒタンパク質およびその使用 | |
| Smyth et al. | Expression of recombinant human Met-ase-1: a NK cell-specific granzyme | |
| Malm et al. | Expression of completely γ‐carboxylated and β‐hydroxylated recombinant human vitamin‐K‐dependent protein S with full biological activity | |
| McGraw et al. | Antigenic determinant in human coagulation factor IX: immunological screening and DNA sequence analysis of recombinant phage map a monoclonal antibody to residues 111 through 132 of the zymogen | |
| US5500344A (en) | Serine protease and uses thereof | |
| ZA200304741B (en) | Von willebrand factor (vWF) cleaving protease polypeptide, nucleic acid encoding the polypeptide and use of polypeptide. | |
| US20050043254A1 (en) | Novel serine protease inhibitory protein mt0039 | |
| Drohan et al. | Recombinant Technology in Hemostasis and Thrombosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC4A | Assignment and transfer of rights |
Owner name: BAXALTA GMBH, GLATTPARK (OPFIKON), CH Free format text: FORMER OWNER: BAXALTA INNOVATIONS GMBH, VIENNA, AT Effective date: 20160314 Owner name: BAXALTA INCORPORATED, BANNOCKBURN, IL, US Free format text: FORMER OWNER: BAXALTA INNOVATIONS GMBH, VIENNA, AT Effective date: 20160314 |
|
| TC4A | Change of owner's name |
Owner name: BAXALTA INNOVATIONS GMBH, VIENNA, AT Effective date: 20160816 |
|
| TE4A | Change of owner's address |
Owner name: BAXALTA GMBH, ZUG, CH Effective date: 20180808 Owner name: BAXALTA INCORPORATED, BANNOCKBURN, IL, US Effective date: 20180808 |
|
| MK4A | Patent expired |
Expiry date: 20211120 |